396 related articles for article (PubMed ID: 26666922)
1. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
[TBL] [Abstract][Full Text] [Related]
2. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.
Choi SH; Park KS; Kim YJ
J Infect Chemother; 2019 Jul; 25(7):514-519. PubMed ID: 30885457
[TBL] [Abstract][Full Text] [Related]
3. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus entry inhibitors targeting the F protein.
Sun Z; Pan Y; Jiang S; Lu L
Viruses; 2013 Jan; 5(1):211-25. PubMed ID: 23325327
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
6. Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
Blockus S; Sake SM; Wetzke M; Grethe C; Graalmann T; Pils M; Le Goffic R; Galloux M; Prochnow H; Rox K; Hüttel S; Rupcic Z; Wiegmann B; Dijkman R; Rameix-Welti MA; Eléouët JF; Duprex WP; Thiel V; Hansen G; Brönstrup M; Haid S; Pietschmann T
Antiviral Res; 2020 May; 177():104774. PubMed ID: 32197980
[TBL] [Abstract][Full Text] [Related]
7. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
Mackman RL; Sangi M; Sperandio D; Parrish JP; Eisenberg E; Perron M; Hui H; Zhang L; Siegel D; Yang H; Saunders O; Boojamra C; Lee G; Samuel D; Babaoglu K; Carey A; Gilbert BE; Piedra PA; Strickley R; Iwata Q; Hayes J; Stray K; Kinkade A; Theodore D; Jordan R; Desai M; Cihlar T
J Med Chem; 2015 Feb; 58(4):1630-43. PubMed ID: 25574686
[TBL] [Abstract][Full Text] [Related]
8. Two novel fusion inhibitors of human respiratory syncytial virus.
Lundin A; Bergström T; Bendrioua L; Kann N; Adamiak B; Trybala E
Antiviral Res; 2010 Dec; 88(3):317-24. PubMed ID: 20965215
[TBL] [Abstract][Full Text] [Related]
9. GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein.
Samuel D; Xing W; Niedziela-Majka A; Wong JS; Hung M; Brendza KM; Perron M; Jordan R; Sperandio D; Liu X; Mackman R; Sakowicz R
Antimicrob Agents Chemother; 2015 Nov; 59(11):7109-12. PubMed ID: 26324264
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
Huang K; Incognito L; Cheng X; Ulbrandt ND; Wu H
J Virol; 2010 Aug; 84(16):8132-40. PubMed ID: 20519399
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection.
Jordan R; Shao M; Mackman RL; Perron M; Cihlar T; Lewis SA; Eisenberg EJ; Carey A; Strickley RG; Chien JW; Anderson ML; McEligot HA; Behrens NE; Gershwin LJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4889-900. PubMed ID: 26055364
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein.
Yang Q; Xue B; Liu F; Lu Y; Tang J; Yan M; Wu Q; Chen R; Zhou A; Liu L; Liu J; Qu C; Wu Q; Fu M; Zhong J; Dong J; Chen S; Wang F; Zhou Y; Zheng J; Peng W; Shang J; Chen X
Signal Transduct Target Ther; 2024 Jun; 9(1):144. PubMed ID: 38853183
[TBL] [Abstract][Full Text] [Related]
13. Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex.
Cox RM; Toots M; Yoon JJ; Sourimant J; Ludeke B; Fearns R; Bourque E; Patti J; Lee E; Vernachio J; Plemper RK
J Biol Chem; 2018 Oct; 293(43):16761-16777. PubMed ID: 30206124
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of respiratory syncytial virus infections: the final breakthrough.
De Clercq E
Int J Antimicrob Agents; 2015 Mar; 45(3):234-7. PubMed ID: 25684638
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.
Coates M; Brookes D; Kim YI; Allen H; Fordyce EAF; Meals EA; Colley T; Ciana CL; Parra GF; Sherbukhin V; Stockwell JA; Thomas JC; Hunt SF; Anderson-Dring L; Onions ST; Cass L; Murray PJ; Ito K; Strong P; DeVincenzo JP; Rapeport G
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652242
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants.
Yoshida I; Arikawa K; Honma Y; Inatani S; Yoshinaga M; Sugiyama H
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046486
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane.
Tang W; Li M; Liu Y; Liang N; Yang Z; Zhao Y; Wu S; Lu S; Li Y; Liu F
FASEB J; 2019 Mar; 33(3):4287-4299. PubMed ID: 30571312
[TBL] [Abstract][Full Text] [Related]
18. Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells.
Cortjens B; Yasuda E; Yu X; Wagner K; Claassen YB; Bakker AQ; van Woensel JBM; Beaumont T
J Virol; 2017 May; 91(10):. PubMed ID: 28275185
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus disease: prevention and treatment.
Chu HY; Englund JA
Curr Top Microbiol Immunol; 2013; 372():235-58. PubMed ID: 24362693
[TBL] [Abstract][Full Text] [Related]
20. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms.
Douglas JL; Panis ML; Ho E; Lin KY; Krawczyk SH; Grant DM; Cai R; Swaminathan S; Chen X; Cihlar T
Antimicrob Agents Chemother; 2005 Jun; 49(6):2460-6. PubMed ID: 15917547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
